Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 329.89 USD -3.02% Market Closed
Market Cap: 177.6B USD

Amgen Inc
Total Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Amgen Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Amgen Inc
NASDAQ:AMGN
Total Assets
$90.1B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
2%
Abbvie Inc
NYSE:ABBV
Total Assets
$133.9B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Total Assets
$58.5B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Total Assets
$4.9B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Assets
$24.9B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Assets
$40.2B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
23%
No Stocks Found

Amgen Inc
Glance View

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
304.81 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Amgen Inc's Total Assets?
Total Assets
90.1B USD

Based on the financial report for Sep 30, 2025, Amgen Inc's Total Assets amounts to 90.1B USD.

What is Amgen Inc's Total Assets growth rate?
Total Assets CAGR 10Y
2%

Over the last year, the Total Assets growth was -1%. The average annual Total Assets growth rates for Amgen Inc have been 12% over the past three years , 7% over the past five years , and 2% over the past ten years .

Back to Top